Literature DB >> 18383846

Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status.

Makoto Kobayashi1, Tamotsu Takeuchi, Yuji Ohtsuki.   

Abstract

UNLABELLED: The incidence of mesothelioma is estimated to rise sharply worldwide, including Japan, in the next two decades. Molecular and proteomic studies are urgently required to elucidate the pathobiology of malignant mesothelioma. This paper describes the characterization of novel human malignant pleural mesothelioma cell lines representing the sarcomatoid, epithelioid and biphasic subtypes.
MATERIALS AND METHODS: Established pleural effusion fluid cell lines were observed using phase-contrast microscopy and transmission electron microscopy. The immunoreactivity of the cells was evaluated using immunohistochemistiy, FACS analysis and Western blotting. The expression of SV40 large cell antigen and the EGFR mutation status were also analyzed.
RESULTS: The cell lines had different morphological and immunophenotypic characteristics. All cell lines showed immunophenotypic marker expression of vimentin, mesothelin and N-cadherin, but no expression of CEA or E-cadherin. At the electron microscopic level, a cell surface rich in microvilli confirmed mesothelial origin of the cell lines. Karyotype analyses showed complex abnormalities in all cell lines. Neither EGFR mutations relevant to tyrosine kinase inhibitor responsiveness nor the expression of SV40 large cell antigen was detected in any of the cell lines.
CONCLUSION: FACS analysis is more sensitive for evaluating mesothelin expression than immunohistochemistry of cut specimens. Irrespective of the expression of EGFR on FACS analysis, no EGFR mutation was detected. These three cell lines may be useful for studying cellular, molecular and genetic aspects of mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18383846

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy.

Authors:  Jedd M Hillegass; Steven R Blumen; Kai Cheng; Maximilian B MacPherson; Vlada Alexeeva; Sherrill A Lathrop; Stacie L Beuschel; Jeremy L Steinbacher; Kelly J Butnor; Maria E Ramos-Niño; Arti Shukla; Ted A James; Daniel J Weiss; Douglas J Taatjes; Harvey I Pass; Michele Carbone; Christopher C Landry; Brooke T Mossman
Journal:  Int J Cancer       Date:  2010-11-03       Impact factor: 7.396

2.  Silencing VDAC1 to Treat Mesothelioma Cancer: Tumor Reprograming and Altering Tumor Hallmarks.

Authors:  Swaroop Kumar Pandey; Renen Machlof-Cohen; Manikandan Santhanam; Anna Shteinfer-Kuzmine; Varda Shoshan-Barmatz
Journal:  Biomolecules       Date:  2022-06-27

3.  Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines.

Authors:  David Cl Lam; Susan Y Luo; Wen Deng; Johnny Sh Kwan; Jaime Rodriguez-Canales; Annie Lm Cheung; Grace Hw Cheng; Chi-Ho Lin; Ignacio I Wistuba; Pak C Sham; Thomas Sk Wan; Sai-Wah Tsao
Journal:  Onco Targets Ther       Date:  2015-01-16       Impact factor: 4.147

4.  Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.

Authors:  Neetu Kalra; Jingli Zhang; Anish Thomas; Liqiang Xi; Mitchell Cheung; Jacqueline Talarchek; Sandra Burkett; Maria G Tsokos; Yuanbin Chen; Mark Raffeld; Markku Miettinen; Ira Pastan; Joseph R Testa; Raffit Hassan
Journal:  BMC Cancer       Date:  2015-05-08       Impact factor: 4.430

5.  Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease.

Authors:  T Chernova; X M Sun; I R Powley; S Galavotti; S Grosso; F A Murphy; G J Miles; L Cresswell; A V Antonov; J Bennett; A Nakas; D Dinsdale; K Cain; M Bushell; A E Willis; M MacFarlane
Journal:  Cell Death Differ       Date:  2016-02-19       Impact factor: 15.828

6.  Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells.

Authors:  Rosanna Mezzapelle; Eltjona Rrapaj; Elena Gatti; Chiara Ceriotti; Francesco De Marchis; Alessandro Preti; Antonello E Spinelli; Laura Perani; Massimo Venturini; Silvia Valtorta; Rosa Maria Moresco; Lorenza Pecciarini; Claudio Doglioni; Michela Frenquelli; Luca Crippa; Camilla Recordati; Eugenio Scanziani; Hilda de Vries; Anton Berns; Roberta Frapolli; Renzo Boldorini; Maurizio D'Incalci; Marco E Bianchi; Massimo P Crippa
Journal:  Sci Rep       Date:  2016-03-10       Impact factor: 4.379

7.  Preoperative serum carcinoembryonic antigen levels are associated with histologic subtype, EGFR mutations, and ALK fusion in patients with completely resected lung adenocarcinoma.

Authors:  Zeng Wang; Shifeng Yang; Hongyang Lu
Journal:  Onco Targets Ther       Date:  2017-07-07       Impact factor: 4.147

8.  Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments.

Authors:  Nikolaos I Kanellakis; Rachelle Asciak; Megat Abd Hamid; Xuan Yao; Mark McCole; Simon McGowan; Elena Seraia; Stephanie Hatch; Rob J Hallifax; Rachel M Mercer; Eihab O Bedawi; Stephanie Jones; Clare Verrill; Melissa Dobson; Vineeth George; Georgios T Stathopoulos; Yanchun Peng; Daniel Ebner; Tao Dong; Najib M Rahman; Ioannis Psallidas
Journal:  Thorax       Date:  2020-09-17       Impact factor: 9.139

9.  Peritoneal Malignant Mesothelioma with Epithelioid Type, Demonstrating High Serum and Ascitic KL-6 Levels: Immunohistochemical Analyses.

Authors:  Saifun Nahar; Manabu Nakamoto; Akira Hokama; Chiharu Kobashigawa; Masatoshi Kaida; Tetsu Kinjo; Tetsuo Hirata; Nagisa Kinjo; Masanao Saio; Naoki Yoshimi; Yuji Ohtsuki; Jiro Fujita
Journal:  Rare Tumors       Date:  2015-09-07

Review 10.  Use of preclinical models for malignant pleural mesothelioma.

Authors:  Marie Shamseddin; Joanna Obacz; Mathew J Garnett; Robert Campbell Rintoul; Hayley Elizabeth Francies; Stefan John Marciniak
Journal:  Thorax       Date:  2021-03-10       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.